Compare DexCom, Inc. (DXCM) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Under Armour Inc Class A — how do they compare? DexCom, Inc. trades at $84.16 (market cap $31.86B), while Under Armour Inc Class A trades at $4.92 (market cap $2.07B). The key difference: DexCom, Inc. is far larger — about 15.4× Under Armour Inc Class A's market cap, and DexCom, Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Under Armour Inc Class A for 99 Days on average.
| DXCM | UAA | |
|---|---|---|
Market Cap | $31.86B | $2.07B |
Volume | 3,607,070 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $8.14 |
52-Week Low | $54.84 | $4.17 |
Typical Hold Time | 62 Days | 99 Days |
Enterprise Value | $31.32B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Under Armour (UAA) trades at $4.94, up 2.49% today, as the company navigates a challenging turnaround. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while technical indicators show a bullish trend despite negative profitability metrics. The company faces revenue declines but maintains margin improvement focus, with analyst consensus leaning toward Hold amid ongoing transformation efforts.
The outlook remains cautious with revenue weakness offset by cost discipline. Investment opportunity exists if margin gains translate to sustained profitability, but risks include persistent demand softness and high debt levels. Current valuation appears reasonable with P/S of 0.42, though negative ROE and net margins warrant careful monitoring of the brand transformation progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
